SAN DIEGO—(BUSINESS WIRE)—Nov. 30, 2015—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system (CNS)disorders, today announced Edmund P. Harrigan, M.D., has joined itsBoard of Directors. Dr. Harrigan is a board-certified neurologist with25 years of executive leadership experience in the pharmaceuticalindustry, most recently serving as Senior Vice President, WorldwideSafety and Regulatory at Pfizer Inc.
“Ed’s extensive experience with CNS drug development, coupled with hisleadership roles in worldwide regulatory and business developmentoperations will be invaluable to ACADIA as we deliver on our vision ofbuilding a leading CNS company dedicated to improving the lives ofpatients through innovative new medicines,” said Leslie L. Iversen,Ph.D., Chairman of ACADIA’s Board of Directors.
Dr. Harrigan’s executive roles at Pfizer span over 18 years and acrossmultiple functions. He served as Senior Vice President of WorldwideSafety and Regulatory for Pfizer from 2012 to 2015, where he led a3,500-person team in 80 countries that was responsible for collecting,interpreting and reporting clinical safety data for more than 600marketed products, and managed regulatory interactions with globalhealth agencies. Dr. Harrigan’s previous executive leadership roles atPfizer include serving as Senior Vice President, Head of WorldwideBusiness Development, Senior Vice President, Head of WorldwideRegulatory Affairs and Quality Assurance, and Vice President, Head ofNeuroscience and Ophthalmology. Earlier in his career at Pfizer, Dr.Harrigan served as Vice President of Clinical Development, TherapeuticArea Head, CNS and Pain.
Before entering the pharmaceutical industry in 1990, Dr. Harrigan was apracticing neurologist for seven years. He currently serves on the Boardof Directors of Karuna Pharmaceuticals Inc. Dr. Harrigan earned his B.A.degree in Chemistry from St. Anselm College and holds an M.D. from theUniversity of Massachusetts at Worcester. He also attended the BrainResearch Institute at the University of California, Los Angeles.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA has a pipeline of productcandidates led by NUPLAZID™ (pimavanserin), for which we have submitteda New Drug Application (NDA) in Parkinson’s disease psychosis to the FDAand which has the potential to be the first drug approved in the UnitedStates for this condition. The FDA has classified the NUPLAZID NDA ashaving Priority Review status. Pimavanserin is also in Phase IIdevelopment for Alzheimer’s disease psychosis and has successfullycompleted a Phase II trial in schizophrenia. ACADIA also hasclinical-stage programs for glaucoma and, in collaboration withAllergan, Inc., for chronic pain. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the potential for NUPLAZID(pimavanserin) to be the first drug approved in the United States forParkinson’s disease psychosis (PDP) and the potential timing of suchapproval, if approved at all, by the FDA; the benefits to ACADIA of Dr.Harrigan joining its Board of Directors; the progress, timing andresults of ACADIA’s drug discovery and development programs, eitheralone or with a partner, including the progress and expected timing ofclinical trials; and the benefits to be derived from ACADIA’s productcandidates, including pimavanserin. These statements are onlypredictions based on current information and expectations and involve anumber of risks and uncertainties. Actual events or results may differmaterially from those projected in any of such statements due to variousfactors, including the risks and uncertainties inherent in drugdiscovery, development, approval and commercialization, andcollaborations with others, and the fact that past results of clinicaltrials and past regulatory decisions may not be indicative of futuretrial results or future regulatory decisions, respectively. For adiscussion of these and other factors, please refer to ACADIA’s annualreport on Form 10-K for the year ended December 31, 2014 as well asACADIA’s subsequent filings with the Securities and Exchange Commission.You are cautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution is madeunder the safe harbor provisions of the Private Securities LitigationReform Act of 1995. All forward-looking statements are qualified intheir entirety by this cautionary statement and ACADIA undertakes noobligation to revise or update this press release to reflect events orcircumstances after the date hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director ofInvestor Relations
(858) 558-2871